Literature DB >> 29673128

Synthesis, analytical characterization, and monoamine transporter activity of the new psychoactive substance 4-methylphenmetrazine (4-MPM), with differentiation from its ortho- and meta- positional isomers.

Gavin McLaughlin1,2, Michael H Baumann3, Pierce V Kavanagh1, Noreen Morris4, John D Power1,2, Geraldine Dowling1,5, Brendan Twamley6, John O'Brien6, Gary Hessman6, Folker Westphal7, Donna Walther3, Simon D Brandt8.   

Abstract

The availability of new psychoactive substances (NPS) on the recreational drug market continues to create challenges for scientists in the forensic, clinical and toxicology fields. Phenmetrazine (3-methyl-2-phenylmorpholine) and an array of its analogs form a class of psychostimulants that are well documented in the patent and scientific literature. The present study reports on two phenmetrazine analogs that have been encountered on the NPS market following the introduction of 3-fluorophenmetrazine (3-FPM), namely 4-methylphenmetrazine (4-MPM), and 3-methylphenmetrazine (3-MPM). This study describes the syntheses, analytical characterization, and pharmacological evaluation of the positional isomers of MPM. Analytical characterizations employed various chromatographic, spectroscopic, and mass spectrometric platforms. Pharmacological studies were conducted to assess whether MPM isomers might display stimulant-like effects similar to the parent compound phenmetrazine. The isomers were tested for their ability to inhibit uptake or stimulate release of tritiated substrates at dopamine, norepinephrine and serotonin transporters using in vitro transporter assays in rat brain synaptosomes. The analytical characterization of three vendor samples revealed the presence of 4-MPM in two of the samples and 3-MPM in the third sample, which agreed with the product label. The pharmacological findings suggest that 2-MPM and 3-MPM will exhibit stimulant properties similar to the parent compound phenmetrazine, whereas 4-MPM may display entactogen properties more similar to 3,4-methylenedioxymethamphetamine (MDMA). The combination of test purchases, analytical characterization, targeted organic synthesis, and pharmacological evaluation of NPS and their isomers is an effective approach for the provision of data on these substances as they emerge in the marketplace.
Copyright © 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Fluorophenmetrazine; monoamine transporters; new psychoactive substances; phenmetrazine; psychostimulants

Mesh:

Substances:

Year:  2018        PMID: 29673128      PMCID: PMC7316143          DOI: 10.1002/dta.2396

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  20 in total

1.  Test purchase, synthesis and characterization of 3-fluorophenmetrazine (3-FPM) and differentiation from its ortho- and para-substituted isomers.

Authors:  Gavin McLaughlin; Noreen Morris; Pierce V Kavanagh; Geraldine Dowling; John D Power; Brendan Twamley; John O'Brien; Brian Talbot; Harald H Sitte; Simon D Brandt
Journal:  Drug Test Anal       Date:  2016-01-26       Impact factor: 3.345

2.  Steric parameters, molecular modeling and hydropathic interaction analysis of the pharmacology of para-substituted methcathinone analogues.

Authors:  F Sakloth; R Kolanos; P D Mosier; J S Bonano; M L Banks; J S Partilla; M H Baumann; S S Negus; R A Glennon
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

3.  A note on the identification of N-hydroxyphenmetrazine as a metabolic product of phendimetrazine and phenmetrazine.

Authors:  A H Beckett; M A Salami
Journal:  J Pharm Pharmacol       Date:  1972-11       Impact factor: 3.765

4.  N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability.

Authors:  Ernesto Solis; John S Partilla; Farhana Sakloth; Iwona Ruchala; Kathryn L Schwienteck; Louis J De Felice; Jose M Eltit; Richard A Glennon; S Stevens Negus; Michael H Baumann
Journal:  Neuropsychopharmacology       Date:  2017-05-22       Impact factor: 7.853

5.  Cocaine-like discriminative stimulus effects of phendimetrazine and phenmetrazine in rats.

Authors:  Clayton T Bauer; S Stevens Negus; Bruce E Blough; Matthew L Banks
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

6.  Adverse events related to the new psychoactive substance 3-fluorophenmetrazine - results from the Swedish STRIDA project.

Authors:  Matilda Bäckberg; Jenny Westerbergh; Olof Beck; Anders Helander
Journal:  Clin Toxicol (Phila)       Date:  2016-08-05       Impact factor: 4.467

7.  Multiple Drug-Toxicity Involving Novel Psychoactive Substances, 3-Fluorophenmetrazine and U-47700.

Authors:  Kayla N Ellefsen; Elizabeth A Taylor; Paul Simmons; Vickie Willoughby; Brad J Hall
Journal:  J Anal Toxicol       Date:  2017-11-01       Impact factor: 3.367

8.  In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates.

Authors:  Richard B Rothman; Nga Vu; John S Partilla; Bryan L Roth; Sandra J Hufeisen; Beth A Compton-Toth; Jon Birkes; Richard Young; Richard A Glennon
Journal:  J Pharmacol Exp Ther       Date:  2003-09-03       Impact factor: 4.030

9.  SHELXT - integrated space-group and crystal-structure determination.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A Found Adv       Date:  2015-01-01       Impact factor: 2.290

10.  Fluorinated phenmetrazine "legal highs" act as substrates for high-affinity monoamine transporters of the SLC6 family.

Authors:  Felix P Mayer; Nadine V Burchardt; Ann M Decker; John S Partilla; Yang Li; Gavin McLaughlin; Pierce V Kavanagh; Walter Sandtner; Bruce E Blough; Simon D Brandt; Michael H Baumann; Harald H Sitte
Journal:  Neuropharmacology       Date:  2017-10-06       Impact factor: 5.273

View more
  4 in total

Review 1.  How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe.

Authors:  Raquel Santos-Toscano; Amira Guirguis; Colin Davidson
Journal:  Br J Clin Pharmacol       Date:  2020-02-23       Impact factor: 4.335

Review 2.  Interpol review of controlled substances 2016-2019.

Authors:  Nicole S Jones; Jeffrey H Comparin
Journal:  Forensic Sci Int Synerg       Date:  2020-05-24

3.  Chronic phenmetrazine treatment promotes D2 dopaminergic and α2-adrenergic receptor desensitization and alters phosphorylation of signaling proteins and local cerebral glucose metabolism in the rat brain.

Authors:  Bradley M Keegan; Annie L Dreitzler; Tammy Sexton; Thomas J R Beveridge; Hilary R Smith; Mack D Miller; Bruce E Blough; Linda J Porrino; Steven R Childers; Allyn C Howlett
Journal:  Brain Res       Date:  2021-02-23       Impact factor: 3.610

Review 4.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.